Several antibodies for blocking PD-1 (such as pembrolizumab and nivolumab) and PD-L1 (such as atezolizumab and avelumab) are FDA approved for clinical use against various cancers, including head and neck cancer, melanoma, and lung cancer (2–5). Here, CD274 is linked to cancer.